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Background/aim: To investigate serum asymmetric dimethyl arginine (ADMA) levels in maintenance hemodialysis (HD) patients and
to assess their potential correlations with C-reactive protein (CRP), albumin, and cholesterol levels as the established cardiovascular
and nutritional parameters.
Materials and methods: Forty-nine patients on maintenance HD treatment and 22 healthy volunteers with similar age and sex
characteristics were recruited into the study. Serum albumin, CRP, creatinine, calcium, phosphate, total cholesterol, low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, hemoglobin, white blood cell counts, and serum ADMA
levels were measured.
Results: HD patients had significantly higher ADMA levels compared with healthy controls (0.51 ± 0.25 vs. 0.35 ± 0.15, P = 0.002).
While white blood cell counts and body mass index values were similar between the 2 groups, CRP and LDL cholesterol were
significantly higher and albumin and HDL cholesterol were significantly lower in HD patients compared with healthy controls. ADMA
concentrations were positively correlated with mean age (P = 0.02, r = 0.360), LDL cholesterol levels (P = 0.006, r = 0.325), and CRP
levels (P = 0.02, r = 0.268) and negatively correlated with serum albumin levels (P = 0.005, r = –0.331).
Conclusion: ADMA levels were found to be higher in HD patients and were shown to be correlated with preestablished inflammatory
and nutritional biomarkers.
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1. Introduction
Patients with chronic kidney disease (CKD) of any
stage have significantly increased risk of accelerated
atherosclerosis and increased cardiovascular mortality
rate (1). In end-stage renal disease (ESRD) patients, more
than half of all deaths are related to cardiac events and this
rate is extremely higher than the rate among the general
population (1). The high prevalence of cardiovascular
mortality in this group of patients could not be easily
explained by traditional risk factors such as diabetes,
hypertension, and dyslipidemia. Recently, there have
been considerable data supporting the idea that chronic
inflammation is a nontraditional risk factor contributing
to the accelerated atherosclerosis in CKD patients
(2,3). Predicting the cardiovascular risk earlier in CKD
patients is crucial in order to decrease the prevalence of
cardiovascular events (4).
Endothelium-derived nitric oxide (NO) is a major
regulator of vascular dilatation and is derived from
* Correspondence: salihinal@yahoo.com

606

arginine by nitric oxide synthase (5). Via the vasodilator
effects, NO reduces both afterload and preload, resulting
in prevention of left ventricular hypertrophy (6). Besides
being an endothelial-based strong vasodilator, it also
inhibits leukocyte adhesion to vascular walls, thrombocyte
aggregation, and vascular smooth muscle cell proliferation
(5). Asymmetric dimethyl arginine (ADMA) is an
endogenous competitive inhibitor of endothelial-based
NO synthase and by reducing NO production it may
promote endothelial dysfunction, hypertension, and
atherosclerosis (7).
ADMA is partially eliminated by the kidneys; therefore,
renal failure increases its level (7). In previous studies,
ADMA levels were found to be higher in ESRD patients
both on peritoneal dialysis and hemodialysis (HD)
compared with healthy controls (8,9). Increased levels of
ADMA are thought to be associated with the increased
frequency of cardiovascular events seen in ESRD patients
(10,11), and it is suggested that ADMA might be a novel
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cardiovascular risk factor for both ESRD patients and
the general population (7,12). Additionally, its relation
with nutritional status in maintenance HD patients was
assessed in a recent trial and a negative correlation was
found between ADMA levels and nutritional parameters
(13).
The objective of our study was to investigate serum
ADMA levels in patients with ESRD who were on chronic
HD treatment and to assess their potential correlations
with C-reactive protein (CRP), albumin, and cholesterol
levels as the established cardiovascular and nutritional
parameters.
2. Materials and methods
This cross-sectional, single-center study enrolled
maintenance HD patients and healthy control subjects.
Seventy-six prevalent HD patients treated at our institute
were screened. Exclusion criteria were history or existence
of malignancy, chronic liver diseases, autoimmune
diseases, symptoms of active infection or inflammation,
hepatitis B and C virus infection, and steroid treatment.
Forty-nine adult HD patients (18–80 years of age) who
fulfilled the inclusion criteria were recruited into the study.
The study protocol was approved by the Medical Ethics
Committee of Ankara Education and Research Hospital
and was performed in accordance with the principles of
the Helsinki Declaration. Informed consent was obtained
from all participants.
Forty-nine patients were on maintenance HD treatment
3 times weekly for 4 h with standard bicarbonate dialysate
and with synthetic membranes. Twenty-two healthy
volunteers, with similar age and sex characteristics and
without any clinical signs of chronic disease or laboratory
abnormality were recruited as controls from subjects who
were admitted to our hospital for routine examination.
Demographic and clinical data were recorded for all
subjects and body mass index (BMI) was calculated as
the ratio of weight (kg) to the square of height (m). Blood
samples were drawn after 12 h of fasting, once after the
weekend. Serum albumin, CRP, creatinine, calcium,
phosphate, total cholesterol, low-density lipoprotein (LDL)
cholesterol, high- density lipoprotein (HDL) cholesterol,
hemoglobin, and white blood cell counts were measured
by using standard methods in a routine biochemistry
laboratory. Serum samples that were separated for ADMA
measurement were stored at –70 °C for a short period of
time, and the tests were performed by the enzyme-linked
immunosorbent assay (ELISA) method (ADMA ELISA
Kit, Immundiagnostik, Bensheim, Germany).
2.1. Statistical analysis
Data were presented as means ± standard deviations.
Comparisons of numeric variables between groups were
performed by Student’s t-test or the Mann–Whitney U

test, as appropriate. Categorical variables were compared
using the chi-squared test and were shown as frequency
and percentages. Univariate correlation was established by
using either Pearson’s or Spearman’s correlation coefficient.
All statistical calculations were performed using SPSS 13.
All P-values were calculated as 2-sided, and P < 0.05 was
considered significant.
3. Results
The present study involved 49 prevalent HD patients and 22
age- and sex-matched controls. Mean age was 55.3 ± 14.2
years for HD patients and 49.3 ± 15.0 years for the control
group (P = 0.11). The patients were on HD treatment for
64.1 ± 4.5 months on average. Primary causes of ESRD
were diabetic nephropathy (n = 21, 42.8%), hypertension
(n = 14, 28.6%), chronic glomerulonephritis (n = 8, 16.3%),
and unknown etiology (n = 6, 12.2%). The anthropometric,
demographic, and biochemical parameters as compared
between the control group and the HD patients are given
in Table 1. HD patients had significantly higher ADMA
levels compared with healthy controls (0.51 ± 0.25 vs.
0.35 ± 0.15, P = 0.002). While white blood cell counts and
BMI values were similar between the 2 groups, CRP and
LDL cholesterol were found to be significantly higher and
albumin and HDL cholesterol significantly lower in HD
patients compared with healthy controls.
ADMA concentrations were positively correlated with
mean age (P = 0.02, r = 0.360), LDL cholesterol levels (P =
0.006, r = 0.325), and serum CRP levels (P = 0.02, r = 0.268).
Additionally, there was a significant negative correlation
between ADMA concentrations and serum albumin levels
(P = 0.005, r = –0.331). Table 2 shows the correlations of
ADMA with clinical and laboratory parameters and the
Figure illustrates these correlations.
4. Discussion
In our study, serum ADMA levels of chronic HD patients
were found to be significantly higher than those of healthy
controls. This result is consistent with the previous similar
studies in the literature regarding ADMA levels in ESRD
patients (9,14,15). Circulating levels of ADMA had a
positive correlation with levels of CRP. This finding might
suggest that a connection exists between endothelial
dysfunction and inflammation in ESRD patients. Recently
some studies pointed out the association of ADMA
levels with biomarkers of inflammation in some chronic
conditions like familial Mediterranean fever, inflammatory
bowel disease, and chronic kidney disease (16–18).
Additionally, serum ADMA levels were inversely
correlated with serum albumin levels in the present study.
As serum albumin level is a marker of nutritional status,
we think that this result suggests an association between
nutrition and inflammation in ESRD patients. This result
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Table 1. Baseline characteristics and laboratory results of study population.
Variable

HD patients
(n = 49)

Healthy controls
(n = 22)

P-value

Mean age (years)

55.3 ± 14.2

49.3 ± 15.0

0.11

Sex (male/female)

26/23

7/15

0.09

Body mass index (kg/m2)

24.7 ± 3.8

25.6 ± 3.6

0.32

Time on dialysis (months)

64.1 ± 4.5

-

-

Creatinine (mg/dL)

7.50 ± 1.78

0.79 ± 0.25

<0.001

Albumin (g/dL)

3.6 ± 0.3

4.2 ± 0.3

<0.001

Hemoglobin (g/dL)

10.8 ± 1.5

13.4 ± 1.9

<0.001

WBC (U/L)

6810 ± 2019

6787 ± 1384

0.96

LDL cholesterol (mg/dL)

147.7 ± 24.3

132.8 ± 23.7

0.02

HDL cholesterol(mg/dL)

31.1 ± 6.2

46.1 ± 13.4

<0.001

ADMA (µmol/L)

0.51 ± 0.25

0.35 ± 0.15

0.002

CRP (mg/dL)

15.2 ± 17.2

2.7 ± 1.2

<0.001

HD: Hemodialysis, WBC: white blood cell count, LDL: low-density lipoprotein, HDL: high-density
lipoprotein, ADMA: asymmetric dimethyl arginine, CRP: C-reactive protein.

Table 2. Correlations of ADMA with clinical and laboratory
parameters.
Variable

P-value

r

Mean age

0.02

0.360

Body mass index (kg/m2)

0.64

0.056

Time on dialysis (months)

0.67

–0.062

Creatinine (mg/dL)

0.07

0.210

Albumin (g/dL)

0.005

–0.331

Hemoglobin (g/dL)

0.06

–0.220

WBC (U/L)

0.17

–0.162

LDL cholesterol (mg/dL)

0.006

0.325

HDL cholesterol(mg/dL)

0.10

–0.197

CRP (mg/dL)

0.02

0.268

ADMA: Asymmetric dimethyl arginine, WBC: white blood
cell count, LDL: low-density lipoprotein, HDL: high-density
lipoprotein, CRP: C-reactive protein.
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is consistent with the findings of a recent trial studying
nutritional status in HD patients (13). Unlike the results of
similar studies, we could not find any significant relation
between ADMA and BMI (13,19). This may be due to the
small number of patients in our study.
Findings on the relation between circulating ADMA
concentrations and serum cholesterol levels are conflicting.
In one study, ADMA levels were found to be higher in
patients with metabolic syndrome compared with normal
subjects, but no correlation was found between ADMA
and cholesterol levels (20). In another study of ESRD
patients, ADMA showed significant correlation with
serum cholesterol levels (19). Consistent with the latter
report, in our study ADMA showed a positive correlation
with serum LDL cholesterol levels. LDL cholesterol may
have a role in the pathway of the atherosclerotic process
of ADMA.
It is reported that there is a positive and significant
correlation between ADMA levels and carotid intima
media thickness in chronic HD patients (21). In another
study, inflammation and endothelial dysfunction as
assessed by circulating levels of ADMA were found to be
an independent factor for explaining all-cause mortality
and cardiovascular events in ESRD patients (18). Similar
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Figure. Correlations of ADMA levels with LDL cholesterol, mean age, albumin, and CRP level in the whole study population.

to this finding, a recent study also reported that ADMA
level is a death predictor in ESRD patients (22). These
results strengthen the hypothesis that interventions aimed
at preventing endothelial dysfunction and inflammation
may decrease the high cardiovascular risk for these
patients. However, it is still unknown whether lowering
the ADMA levels would be of any clinical benefit.
The limitations of our study are the cross-sectional
design and small sample size. Additionally, some
anthropometric measurements and clinical parameters

representing nutritional status could be added to the
study design. A prospective study with a larger sample size
would be more helpful for this issue.
In conclusion, in the present study we have found
significantly higher serum ADMA levels in chronic HD
patients compared with healthy individuals. Our results
suggest that ADMA might be a potential novel biomarker
of inflammation and atherosclerosis in patients on chronic
HD. Measuring ADMA levels may promote awareness of
early cardiovascular risk increase in HD patients.
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